Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF.
Overall, researchers found that ivabradine was a “safe and effective” POTS treatment associated with making significant improvements to patient heart rates and quality of life.
According to a new study published in Circulation, ablation was associated with numerous benefits over standard drug therapy.
Heart failure patients are also more likely to be readmitted than they were in the recent past.
In fact, drinking decaffeinated coffee was associated with a significant increase in heart failure risk.
Casana, formerly known as Heart Health Intelligence, also named a new CEO.
Two specialists have shared their own perspective on the updated ACC/AHA guidelines in Circulation.
However, treatment with sacubitril/valsartan did not lead to improvements in hospitalizations for heart failure or all-cause mortality.
Calcium supplements, the researchers emphasized, should be prescribed with caution.
The new findings are part of a virtual conference being hosted by the American College of Cardiology.
Sold as Verquvo, the medication can help patients reduce their risk of cardiovascular death or hospitalization for heart failure.
The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19.